New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
07:36 EDTZGNX, DRRXDurect announces positive results from Relday Phase 1 clinical trial
Durect (DRRX) announced that its licensee, Zogenix (ZGNX) reported positive single-dose pharmacokinetic results from the Phase 1 clinical trial of Relday, an investigational candidate of a proprietary, once-monthly subcutaneous formulation of risperidone for the treatment of schizophrenia. According to Zogenix, adverse events in the Phase 1 trial in patients diagnosed with schizophrenia were generally mild to moderate and consistent with other risperidone products.
News For DRRX;ZGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 24, 2015
08:10 EDTDRRXDURECT likely to announce partnership soon, says Cantor
Subscribe for More Information
June 23, 2015
08:05 EDTDRRXDurect to conduct new POSIDUR Phase 3 clinical trial
Durect says based on feedback from the FDA, it plans to conduct a new POSIDUR, or SABER-Bupivacaine, Phase 3 clinical trial consisting of approximately 300 patients undergoing laparoscopic cholecystectomy surgery. DURECT anticipates beginning the trial in the fall of 2015 and expects that it will take approximately one year to complete enrollment. The study will be a randomized, parallel-group, double-blind, placebo-controlled, multicenter trial of POSIDUR in patients undergoing laparoscopic cholecystectomy. The objective of the study will be to evaluate the safety and efficacy of POSIDUR for the management of postoperative pain.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use